Pulmonary Hypertension

Results Support Therapeutic Intra-vascular Ultrasound (TIVUS) for - Pulmonary Hypertension News Results Support Therapeutic Intra-vascular Ultrasound (TIVUS) for - Pulmonary Hypertension News The Significance of Databases for PAH - MD Magazine Grant Will Award Up to $1 Million in Pulmonary Hypertension Research - The Cardiology Advisor Bayer Grant Will Award Up to $1 Million in PAH, CTEPH Research - Pulmonology Advisor Results Support Therapeutic Intra-vascular Ultrasound (TIVUS) for - Pulmonary Hypertension News Posted: 31 May 2019 06:00 AM PDT New data support the safety and effectiveness of TIVUS (therapeutic intra-vascular ultrasound) for patients with pulmonary arterial hypertension (PAH) on a stable treatment regimen. The data were recently presented at the annual meeting of the European Association of Percutaneous Cardiovascular Interventions ( EuroPCR ), in Paris. In PAH,...

Results Support Therapeutic Intra-vascular Ultrasound (TIVUS) for - Pulmonary Hypertension News Results Support Therapeutic Intra-vascular Ultrasound (TIVUS) for - Pulmonary Hypertension News The Significance of Databases for PAH - MD Magazine Owlstone, Actelion Team to Develop Breath-based Test for Diagnosing PH - Pulmonary Hypertension News Results Support Therapeutic Intra-vascular Ultrasound (TIVUS) for - Pulmonary Hypertension News Posted: 31 May 2019 06:00 AM PDT New data support the safety and effectiveness of TIVUS (therapeutic intra-vascular ultrasound) for patients with pulmonary arterial hypertension (PAH) on a stable treatment regimen. The data were recently presented at the annual meeting of the European Association of Percutaneous Cardiovascular Interventions ( EuroPCR ), in Paris. In PAH, small arteries inside the lungs become constricted. This creates resistance, making...

Resverlogix Announces Upcoming Phase 2 Trial on Apabetalone for PH - Pulmonary Hypertension News Resverlogix Announces Upcoming Phase 2 Trial on Apabetalone for PH - Pulmonary Hypertension News Posted: 20 May 2019 12:00 AM PDT Promising preclinical findings recently published in a peer-reviewed journal opened the door to the launch of a Phase 2 trial testing the therapeutic potential of apabetalone (RVX-208), Resverlogix 's proprietary therapy, in people with pulmonary arterial hypertension (PAH). The findings of the study, " Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension ," were published in the American Journal of Respiratory and Critical Care Medicine . Apabetalone is a selective inhibitor of bromodomain and extra-terminal domain (BET) proteins , a group of proteins that regulate gene activity without altering the DNA sequence ( ep...

Prognostic Effects of Imaging Ratios in Idiopathic Pulmonary Fibrosis - Pulmonology Advisor Prognostic Effects of Imaging Ratios in Idiopathic Pulmonary Fibrosis - Pulmonology Advisor Posted: 23 May 2019 02:00 AM PDT Patients with idiopathic pulmonary fibrosis (IPF) who had a ratio of the diameter of the main pulmonary artery to that of the aorta (mPA/Ao) >1 on chest computed tomography (CT) had worse outcomes, according to the results of a recent study published in BMC Pulmonary Medicine . The diameter of the mPA and Ao was measured by chest CT in patients after diagnosis of IPF . Associations between clinical outcomes and the ratio of the diameter of the mPA/Ao were examined retrospectively. The primary outcomes of interest were death and lung transplantation. Among the 303 enrolled participants with IPF, 234 were men and 69 were women. The most common comorbidities were hypertension and diabetes mellitus. The median mPA/Ao ratio wa...

Owlstone Medical, Actelion team up for pulmonary hypertension detection - PharmaTimes Owlstone Medical, Actelion team up for pulmonary hypertension detection - PharmaTimes Posted: 20 May 2019 05:14 AM PDT Owlstone Medical has announced a strategic partnership with Actelion Pharmaceuticals. The global leader in Breath Biopsy for applications in early disease detection announced the collaboration to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes. This development program will be solely funded by Actelion. Currently, early diagnosis of PH is very difficult, and even at an advanced stage presents similar to other heart and lung conditions, so a delay of years between the onset of symptoms and diagnosis and treatment is unfortunately common. The collaboration will initially involve collecting breath exhaled Volatile Organic Compounds (VOCs) from over 1,000 patients usi...

Combination therapy with treprostinil reduced risk for clinical worsening in PAH: FREEDOM EV - Healio Combination therapy with treprostinil reduced risk for clinical worsening in PAH: FREEDOM EV - Healio Posted: 29 May 2019 07:04 AM PDT DALLAS — Adding treprostinil to monotherapy, as compared with placebo, reduced the risk for clinical worsening events in patients with pulmonary artery hypertension, especially after adjustment for baseline risk, new data from FREEDOM EV indicate. The global, event-driven FREEDOM EV trial, which was presented at the American Thoracic Society International Conference by R. James White III, MD, PhD, from the University of Rochester Medical Center in New York, involved 690 patients, all of whom were required to enter the trial on only one oral PAH medication. Upon enrollment, patients were randomly assigned to oral treprostinil (Tyvaso, United Therapeutics Corp.) or placebo, with all receiving at least one ...